United States scientists at Rutgers University have developed a targeted drug delivery system, and they believe that such systems are better able to treat ovarian cancer.

Tamara Minko, Professor Ernest Mario School of Pharmacy and Obstetrics Gynecology and reproductive sciences at Robert Wood Johnson Medical School Professor Lorna Rodriguez says, because there is no good method for ovarian cancer screening, most women suffering from ovarian cancer, until the cancer has moved to other organs can only be confirmed if, surgery and chemotherapy are not very effective at this time.

Provide treatment for patients with ovarian cancer Medical Oncology in obstetrics and Gynecology Rodriguez, Rutgers precision Medical Director of the Cancer Institute of New Jersey, he said: "once resistant ovarian cancer, we cannot cure it. Avoid the development of drug resistance is essential a reasonable method. ”

They said that advanced ovarian cancer is largely due to a runaway CD44 protein, which can cause the proliferation of malignant tumors, have a tolerance to conventional drug therapy. Result: 5-year survival rate in patients with advanced ovarian cancer rates, only 30%.

In the most recent Clinical Cancer Research this latest study published in the journal, Minko and Rodriguez providing the results of animal studies. In these animal studies, they used the small inhibitory RNA molecules – to directly target these molecules and reduce the excessive amounts of CD44 protein in cancer cells, while the use of anticancer drug taxol-treated patients, attacking cancer at the genetic level. This makes the cancer cells within, even at a late stage cancer, have been successfully treated.

Minko said: "We hope we offer such treatments will be particularly effective for advanced ovarian cancer, the stage of the tumor, cancer stem cells regulation have many can withstand conventional medication. ”

In this study, scientists at Rutgers, through laboratory mice injections taken from the Cancer Institute treatment of gynaecological cancer patients of tumor tissue, the establishment of a malignant tumor was found in women with ovarian cancer are very similar to animal models. Then, in order to inhibit tumor growth and preventing their transfer, while still retaining the normal healthy cells, they use the combination of chemotherapy and gene therapy, directly targeting cancer cells. Such therapy kills cancer cells in mice, and shrink their tumors, to leave them with fewer side effects.

Expression of CD44 protein on the surface of many cancer stem cells, Rutgers scientists have developed this method could also help other types of cancer treatments. Next step in ovarian cancer research, will be developed for use in clinical trials of drugs for human consumption. They said this would likely lead to a new cancer drug treatment, and increase the survival rate of the deadly disease.